DDW’s Megan Thomas attended Nebius’ inaugural AI Discovery Awards in Amsterdam, where top prizes of $100,000 in GPU credits were awarded to four companies pioneering AI breakthroughs in cancer prediction, protein targeting, transcriptomic mapping, and precision diagnostics.

The winners were selected from 257 global applications by a panel of 19 independent judges from leading pharmaceutical, biotechnology, research and healthcare organisations including AstraZeneca BioPharma, NVIDIA, Monte Rosa Therapeutics and Utrecht University. The winners represent validated AI solutions with clear paths to market impact.

Drug Discovery

Aikium won with its platform that targets “undruggable” proteins comprising half the human proteome using its Yotta-ML² platform. The company has secured partnerships with four organisations, including three top cancer hospitals, based on successful GPCR proof-of-concept work.

Biotechnology

Ataraxis AI won with its cancer treatment prediction platform that achieved 30% higher accuracy than standard genomic tests in clinical validation across 7,500 patients from 15 institutions. The Kestrel foundation model, trained on hundreds of millions of pathology images, helps oncologists determine whether aggressive treatments like chemotherapy are necessary.

Genomics and multi-omics

Transcripta Bio won for its high-resolution transcriptomic atlas containing over a billion gene responses to power AI models predicting biological responses from drug molecules. The company recently partnered with Microsoft Research to identify new disease-gene associations.

HealthTech

MetaSight Diagnostics are pioneering population-scale disease diagnostics through advanced blood testing, creating the world’s largest blood molecular database from over 500,000 participants in the Israel Multi-OMICS Screening Trial, developing screening products for colorectal cancer and metabolic diseases.

2025 award ceremony 

“These teams are pushing the frontier of AI in healthcare and life sciences with credible science and clear paths to market,” said Arkady Volozh, Founder and CEO of Nebius. “We’re proud to help them turn research into real-world impact.”

Held for the first time in 2025, the Nebius AI Discovery Awards connect promising companies leveraging AI in healthcare and life sciences with the computational infrastructure and expertise needed to scale their innovations.

Category winners received $100,000 in GPU credits for the Nebius AI Cloud, with second- and third-placed companies receiving $50,000 and $30,000, respectively, as well as other benefits including mentorship and networking support.

A further seven ‘honourable mentions’ in each category received $5,000 in GPU cloud credits. All participants in the AI Discovery Awards were also granted inferencing credits for Nebius AI Studio.

“These companies represent meaningful progress in applying AI to healthcare’s most challenging problems,” said Dr Ilya Burkov, Global Head of Healthcare & Life Sciences Growth at Nebius. “From targeting previously undruggable proteins to predicting cancer treatment outcomes with unprecedented accuracy, these teams are building tools that will directly impact patient care and health outcomes.”

‍Megan Thomas, Multimedia Editor, DDW